PolyPeptide shares surge as strong revenue growth prompts guidance upgrade

PolyPeptide Group AG (PPGN) reported robust H1 2025 results, with revenue soaring 23.7% year-over-year to €167.1 million, significantly exceeding analyst expectations due to strong growth in metabolic therapeutics and commercial revenue driven by successful capacity ramp-up. The company subsequently raised its full-year revenue guidance to 13-20% growth. However, H1 EBITDA of €4.4 million missed consensus estimates by €2.5 million, despite a substantial improvement in operating cash flow to €49.7 million. PPGN reaffirmed its ambitious mid-term outlook to double 2023 revenue and achieve a 25% EBITDA margin by 2028, signaling a focus on long-term expansion despite near-term margin pressures.

Analysis

PolyPeptide Group AG (PPGN) reported a robust first half for 2025, characterized by exceptional top-line growth that significantly surpassed market expectations. Revenue surged 23.7% year-over-year to €167.1 million, beating analyst consensus by 12%, driven by a near-doubling of metabolic therapeutics revenue (+98.2%) and a 37.9% increase in commercial revenue. This performance, fueled by the successful ramp-up of new large-scale SPPS capacity, prompted management to raise its full-year revenue growth guidance to 13-20%. However, this growth came at a cost to near-term profitability, as H1 EBITDA of €4.4 million missed consensus estimates by €2.5 million, indicating significant margin pressure despite the revenue beat. The company's financial position was substantially strengthened by a dramatic improvement in operating cash flow to €49.7 million, largely due to €27.7 million in customer prepayments, and an expanded revolving credit facility. This enhanced liquidity provides a crucial buffer for the projected €100 million in annual capital expenditures. Management reaffirmed its ambitious mid-term outlook to double 2023 revenue by 2028 and approach a 25% EBITDA margin, signaling that the current phase is one of aggressive investment for long-term market leadership.

Key Decisions for Investors

• Investors should weigh the compelling top-line momentum, evidenced by the 23.7% revenue growth and raised guidance, against the significant near-term margin pressure highlighted by the H1 EBITDA miss.
• Monitor the company's progress toward its full-year EBITDA margin target in the high single-digit to low double-digit range, as this will be a key test of operational efficiency following the recent capacity expansion.
• The dramatic improvement in operating cash flow, bolstered by customer prepayments, should be viewed as a key positive that mitigates the financial risk associated with the aggressive €100 million capital expenditure plan.
• The investment thesis for PPGN is long-term, requiring confidence in management's ability to convert current investments and revenue growth into its ambitious 2028 targets of doubling revenue and achieving a 25% EBITDA margin.